OCUPRESS
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
May 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OCUPRESS by Novartis is clinical pharmacology carteolol hcl is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. First approved in 1990.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ocupress (carteolol HCl) is a topical ophthalmic solution containing a nonselective beta-adrenergic blocking agent used to reduce intraocular pressure in patients with glaucoma or ocular hypertension. It works by reducing cardiac output and aqueous humor production, achieving median IOP reductions of 22–25% when dosed twice daily. The drug has intrinsic sympathomimetic activity and no significant membrane-stabilizing effects.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a shrinking brand team focused on managed decline.
Mechanism of Action
CLINICAL PHARMACOLOGY Carteolol HCl is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Ocupress (carteolol HCl) reduces normal and elevated intraocular pressure (IOP) whether or not accompanied…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Ocupress offers limited growth potential, with roles concentrated in commercial and business development functions managing a declining asset. Career value lies in managed care strategy, pricing defense, and generic transition planning rather than innovation or market expansion.
Worked on OCUPRESS at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.